Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

Current Hematologic Malignancy Reports

Volumn 5, Issue 4, 2010, Pages 213-221

  Ohno, Ryuzo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acute lymphoblastic leukemia; BCR ABL; Dasatinib; Imatinib; Nilotinib; Philadelphia chromosome; Prognostic factors; TKI; Tyrosine kinase inhibitor

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; HYDROXYUREA; IMATINIB; INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NILOTINIB; PREDNISOLONE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; HUMAN; LUNG EMBOLISM; MULTIPLE CYCLE TREATMENT; PERICARDIAL EFFUSION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PROGNOSIS; REVIEW;

EID: 77958506198     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0061-y     Document Type: Review

References (55)

1. M Wetzler RK Dodge K Mrozek, et al. 1999 Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience Blood 93 3983 3993 1:CAS:528:DyaK1MXjsVOntLw%3D 10339508
2. CH Pui WE Evans 2006 Treatment of acute lymphoblastic leukemia N Engl J Med 354 166 178 1:CAS:528:DC%2BD28XisFWksQ%3D%3D 10.1056/NEJMra052603 16407512 (Pubitemid 43076714)
3. TG Lugo AM Pendergast AJ Muller ON Witte 1990 Tyrosine kinase activity and transformation potency of bcr-abl oncogene products Science 247 1079 1082 1:CAS:528:DyaK3cXhslensbg%3D 10.1126/science.2408149 2408149
4. Ottmann OG, Wassmann B: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005:118-122.
5. M Aricò MG Valsecchi B Camitta, et al. 2000 Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia N Engl J Med 342 998 1006 10.1056/NEJM200004063421402 10749961 (Pubitemid 30180646)
6. M Schrappe M Aricò J Harbott, et al. 1998 Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome Blood 92 2730 2741 1:CAS:528:DyaK1cXms1elt7k%3D 9763557
7. H Dombret J Gabert JM Boiron, et al. 2002 Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial Blood 100 2357 2366 1:CAS:528:DC%2BD38XnvVGis7o%3D 10.1182/blood-2002-03-0704 12239143
8. Goldstone AH, Prentice HG, Durrant J, et al.: Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993 ) [abstract]. Blood 2001, 98:856a.
9. M Tanimoto S Miyawaki T Ino, et al. 1998 Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG) Int J Hematol 68 421 429 1:STN:280: DyaK1M7gt1yhtQ%3D%3D 10.1016/S0925-5710(98)00084-X 9885441 (Pubitemid 28559119)
10. T Ueda S Miyawaki N Asou, et al. 1998 Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group Int J Hematol 68 279 289 1:CAS:528:DyaK1cXotVWlsLs%3D 10.1016/S0925-5710(98)00075-9 9846012 (Pubitemid 28522553)
11. J Takeuchi T Kyo K Naito, et al. 2002 Induction therapy by frequent administration of doxorubicin with four other drugs followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study Leukemia 16 1259 1266 1:CAS:528:DC%2BD38XkvFKrtr8%3D 10.1038/sj.leu.2402526 12094249
12. H Kantarjian D Thomas S O'Brien, et al. 2004 Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia Cancer 101 2788 2801 1:CAS:528:DC%2BD2MXivFOhuw%3D%3D 10.1002/cncr.20668 15481055 (Pubitemid 39603187)
13. Thomas DA: Philadelphia chromosome-positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program 2007:435-443.
14. BJ Druker F Guilhot SG O'Brien, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417 1:CAS:528:DC%2BD28Xht12ntrzM 10.1056/NEJMoa062867 17151364 (Pubitemid 44903745)
15. R Ohno 2006 Treatment of chronic myeloid leukemia with imatinib mesylate Int J Clin Oncol 11 176 183 1:CAS:528:DC%2BD28XntVGisr4%3D 10.1007/s10147-006- 0582-5 16850123 (Pubitemid 44087115)
16. OG Ottmann BJ Druker CL Sawyers, et al. 2002 A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias Blood 100 1965 1971 1:CAS:528:DC%2BD38Xnt1yiu7Y%3D 10.1182/blood-2001-12-0181 12200353 (Pubitemid 35001224)
17. R Ohno 2006 Japan Adult Leukemia Study Group: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy Curr Hematol Malig Rep 1 180 187 10.1007/s11899-996-0006-7 20425349 (Pubitemid 44623864)
18. R Ohno 2008 Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia Curr Oncol Rep 10 379 387 1:CAS:528:DC%2BD1cXhtFKntLvM 10.1007/s11912-008-0059-y 18706265
19. M Yanada R Ohno T Naoe 2009 Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia Int J Hematol 89 3 13 1:CAS:528:DC%2BD1MXkvVWjtA%3D%3D 10.1007/s12185-008-0223-z 19093166
20. M Towatari M Yanada N Usui, et al. 2004 Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia Blood 104 3507 3512 1:CAS:528:DC%2BD2cXhtVGltLfF 10.1182/blood-2004-04-1389 15315963 (Pubitemid 39564420)
21. M Yanada J Takeuchi I Sugiura, et al. 2006 High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group J Clin Oncol 24 460 466 1:CAS:528: DC%2BD28XhsFSku7c%3D 10.1200/JCO.2005.03.2177 16344315 (Pubitemid 46630465)
22. M Yanada I Sugiura J Takeuchi, et al. 2008 Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy Br J Haematol 143 503 510 18986386
23. DA Thomas S Faderl J Cortes, et al. 2004 Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood 103 4396 4407 1:CAS:528:DC%2BD2cXlt1KrsLg%3D 10.1182/blood-2003- 08-2958 14551133 (Pubitemid 38745962)
24. B Wassmann H Pfeifer N Goekbuget, et al. 2006 Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph∈+∈ALL) Blood 108 1469 1477 1:CAS:528:DC%2BD28Xpt1Slt78%3D 10.1182/blood-2005-11-4386 16638934 (Pubitemid 44316110)
25. A de Labarthe P Rousselot F Huguet-Rigal, et al. 2007 Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study Blood 109 1408 1413 10.1182/blood-2006-03-011908 17062730 (Pubitemid 46239571)
26. JM Ribera A Oriol M González 2010 Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial Haematologica 95 87 95 1:CAS:528: DC%2BC3cXitlals7o%3D 10.3324/haematol.2009.011221 19797728
27. M Vignetti P Fazi G Cimino, et al. 2007 Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol Blood 109 3676 3678 1:CAS:528: DC%2BD2sXkvFCitrY%3D 10.1182/blood-2006-10-052746 17213285 (Pubitemid 46641715)
28. OG Ottmann B Wassmann H Pfeifer, et al. 2007 Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph∈+∈ALL) Cancer 109 2068 2076 1:CAS:528:DC%2BD2sXmtV2qs7c%3D 10.1002/cncr.22631 17429836 (Pubitemid 46745234)
29. A Delannoy E Delabesse V Lhéritier, et al. 2006 Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study Leukemia 20 1526 1532 1:CAS:528:DC%2BD28XosVSjsb8%3D 10.1038/sj.leu.2404320 16838024 (Pubitemid 44264094)
30. KR Schultz WP Bowman A Aledo 2009 Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study J Clin Oncol 27 5175 5181 1:CAS:528: DC%2BD1MXhsFahsLrK 10.1200/JCO.2008.21.2514 19805687
31. M Yanada J Takeuchi I Sugiura, et al. 2008 Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy Haematologica 93 287 290 10.3324/haematol.11891 18223280 (Pubitemid 351397719)
32. B Wassmann H Pfeifer M Stadler, et al. 2005 Early molecular response to posttransplantation imatinib determines outcome in MRD∈+∈Philadelphia- positive acute lymphoblastic leukemia (Ph∈+∈ALL) Blood 106 458 463 1:CAS:528:DC%2BD2MXmtleqsLY%3D 10.1182/blood-2004-05-1746 15817679 (Pubitemid 40981238)
33. S Lee YJ Kim NG Chung, et al. 2009 The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia Cancer 115 561 570 1:CAS:528:DC%2BD1MXislKisrw%3D 10.1002/cncr.24026 19117346
34. T O'Hare CA Eide MW Deininger 2007 Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 110 2242 2249 10.1182/blood-2007-03-066936 17496200 (Pubitemid 47523141)
35. S Branford Z Rudzki S Walsh, et al. 2003 Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood 102 276 283 1:CAS:528: DC%2BD3sXltFemu7k%3D 10.1182/blood-2002-09-2896 12623848 (Pubitemid 36759665)
36. T O'Hare DK Walters EP Stoffregen, et al. 2005 In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 65 4500 4505 10.1158/0008-5472.CAN-05-0259 15930265 (Pubitemid 40740783)
37. H Pfeifer B Wassmann A Pavlova, et al. 2007 Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph∈+∈ALL) Blood 110 727 734 1:CAS:528:DC%2BD2sXot1emt7c%3D 10.1182/blood-2006-11-052373 17405907 (Pubitemid 47108165)
38. Y Hu Y Liu S Pelletier, et al. 2004 Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia Nat Genet 36 453 461 1:CAS:528:DC%2BD2cXjsFSnt74%3D 10.1038/ng1343 15098032 (Pubitemid 38620028)
39. M Lindauer A Hochhaus 2010 Dasatinib. Recent Results Cancer Res 184 83 102 10.1007/978-3-642-01222-8-7
40. O Ottmann H Dombret G Martinelli, et al. 2007 Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Blood 110 2309 2315 1:CAS:528:DC%2BD2sXhtFCnsbzK 10.1182/blood-2007-02-073528 17496201 (Pubitemid 47523149)
41. K Porkka P Koskenvesa T Lundán, et al. 2008 Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia Blood 112 1005 1012 1:CAS:528:DC%2BD1cXpvVOksL0%3D 10.1182/blood-2008-02-140665 18477770
42. MB Lilly OG Ottmann NP Shah, et al. 2010 Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study Am J Hematol 85 164 170 1:CAS:528:DC%2BC3cXktlSmtr4%3D 20131302
43. + ALL, but the severe adverse events should not be overlooked.
44. A Quintás-Cardama H Kantarjian F Ravandi 2009 Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy Cancer 115 2482 2490 10.1002/cncr.24257 19280591
45. A Quintás-Cardama X Han H Kantarjian J Cortes 2009 Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia Blood 114 261 263 10.1182/blood-2008-09-180604 19414863
46. + ALL without remarkable adverse events.
47. Ottmann OG, Larson LA, Kantarjian HM: Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph∈+∈ALL) who are resistant or intolerant to imatinib [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:abstract 2815.
48. R Ohno N Asou K Ohnishi 2003 Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate Leukemia 17 1454 1463 1:CAS:528:DC%2BD3sXlslOitbw%3D 10.1038/sj.leu.2403031 12886231 (Pubitemid 36986946)
49. G Riva M Luppi P Barozzi, et al. 2010 Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph∈+∈acute lymphoblastic leukemia during long-term imatinib mesylate treatment Blood 115 1512 1518 10.1182/blood-2009-06-230391 20007806
50. DH Kim S Kamel-Reid H Chang 2009 Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia Haematologica 94 135 139 1:CAS:528:DC%2BD1MXis1Wmtrc%3D 10.3324/haematol.13151 19066329
51. S Mustjoki M Ekblom TP Arstila, et al. 2009 Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy Leukemia 23 1398 1405 1:CAS:528:DC%2BD1MXpvF2kurs%3D 10.1038/leu.2009.46 19295545
52. Y Kano M Akutsu S Tsunoda, et al. 2001 In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly use antileukemic agents Blood 97 1999 2007 1:CAS:528:DC%2BD3MXjvFCqsro%3D 10.1182/blood.V97.7. 1999 11264164 (Pubitemid 32239079)
53. JT Thiesing S Ohno-Jones KS Kolibaba BJ Druker 2000 Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells Blood 96 3195 3199 1:CAS:528:DC%2BD3cXnslGntLs%3D 11050003
54. T Hongo S Okada N Inoue, et al. 2002 Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing Int J Hematol 76 3 251 259 10.1007/BF02982795 12416736
55. Ramakers-van Woerden NL, Pieters R, Hoelzer D, et al.: In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. Med Pediatr Oncol 2002, 38:379-386.